Product image of Kogavant (Ticagrelor) supplied by GNH India

Kogavant

Active Ingredient:
Ticagrelor
Origin:
EU

Kogavant (Ticagrelor)

Ticagrelor, the active ingredient in Kogavant, is a P2Y12 receptor antagonist presented as an oral tablet for oral use. It treats acute coronary syndrome and myocardial infarction, helping to prevent further thrombotic events in at‑risk patients.

GNH India supplies Kogavant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Gedeon Richter Plc.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Kogavant, a P2Y12 receptor antagonist, is employed in the management of coronary artery disease and related thrombotic conditions.

  • Acute coronary syndrome: reduces the risk of cardiovascular death, myocardial infarction and stroke.
  • ST‑elevation myocardial infarction (STEMI): provides rapid antiplatelet effect to limit clot propagation.
  • Non‑ST‑elevation myocardial infarction (NSTEMI): supports early reperfusion and secondary prevention.
  • History of myocardial infarction: lowers the incidence of recurrent thrombotic events.

How It Works

  • Ticagrelor reversibly binds to the platelet P2Y12 ADP receptor, blocking ADP‑mediated activation of the glycoprotein IIb/IIIa complex. This inhibition prevents platelet aggregation and thrombus formation without requiring metabolic activation, offering a rapid and consistent antiplatelet effect across patients.

Side Effects

Common Side Effects

  • Dyspnea: shortness of breath, often mild to moderate.
  • Bleeding: including bruising, nosebleeds, or gastrointestinal bleeding.
  • Headache: transient and usually self‑limiting.
  • Nausea: occasional upset stomach.
  • Dizziness: may occur upon standing.
  • Hypotension: mild drops in blood pressure.

Serious or Rare Side Effects

  • Severe or uncontrolled bleeding: intracranial or fatal hemorrhage.
  • Myocardial infarction recurrence: despite therapy.
  • Hepatic injury: elevated liver enzymes or hepatitis.
  • Thrombocytopenia: marked reduction in platelet count.
  • Allergic reactions: rash, angioedema, anaphylaxis.
  • Cardiac arrhythmias: ventricular or atrial rhythm disturbances.

Precautions & Warnings

Before initiating Kogavant, clinicians should consider the following precautions:

  • Assess bleeding risk: evaluate history of hemorrhage or anticoagulant use.
  • Monitor liver function: check hepatic enzymes periodically.
  • Evaluate renal function: adjust therapy in severe impairment.
  • Avoid in active pathological bleeding: discontinue if bleeding becomes uncontrolled.
  • Use caution in elderly patients: increased susceptibility to adverse events.
  • Store at room temperature: keep in the original pack, protect from moisture.

Avoid Interactions

Kogavant may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ticagrelor exposure.
  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce efficacy.
  • Concomitant anticoagulants (e.g., warfarin, heparin): heighten bleeding risk.

Moderate Interactions (Monitor Closely)

  • NSAIDs: additive bleeding potential.
  • SSRIs or SNRIs: may increase hemorrhagic events.
  • Oral contraceptives: possible pharmacokinetic interaction.
  • Statins (especially high‑dose): modest increase in plasma levels.
  • Digoxin: potential for increased concentration.

Frequently Asked Questions

Kogavant contains ticagrelor, an antiplatelet medication indicated for the treatment of acute coronary syndrome, including both ST‑elevation and non‑ST‑elevation myocardial infarction, and for secondary prevention of thrombotic events in patients with a prior myocardial infarction.

Ticagrelor reversibly blocks the platelet P2Y12 ADP receptor, preventing ADP‑induced activation of the glycoprotein IIb/IIIa complex. This inhibition stops platelets from aggregating, thereby reducing the formation of arterial clots that can cause heart attacks or strokes.

The dosage of Kogavant is determined by the prescribing clinician based on the specific indication, patient weight, renal function, and bleeding risk. Healthcare professionals follow established guidelines and adjust the regimen as needed for each individual.

Safety data for ticagrelor in pregnancy and lactation are limited. It should only be used when the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Kogavant, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with clopidogrel, another P2Y12 inhibitor, ticagrelor provides more rapid and consistent platelet inhibition without needing metabolic activation. It is reversible, offering a quicker offset of effect, but may be associated with a higher incidence of dyspnea and requires attention to drug‑drug interactions involving CYP3A4.

Kogavant should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Kogavant is taken orally with a glass of water. It can be administered with or without food, as directed by the prescriber. Patients should swallow the tablet whole and not split, crush, or chew it unless specifically instructed.

The most serious risks include severe or uncontrolled bleeding, such as intracranial hemorrhage, and rare but potentially fatal allergic reactions. Patients should seek immediate medical attention if they experience unusual bruising, prolonged bleeding, sudden severe headache, or signs of anaphylaxis.

Kogavant is contraindicated in patients with active pathological bleeding, a history of intracranial hemorrhage, severe hepatic impairment, or known hypersensitivity to ticagrelor or any of its excipients. Clinicians should also avoid use in patients receiving strong CYP3A4 inhibitors when alternative therapy is available.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ticagrelor

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT